FLT3-ITD-mutated AML irrespective of the allelic ratio (formerly FLT3-ITDhigh for biallelic mutation and FLT3-ITDlow for mono-allelic mutation) or the concurrent NMP1 mutation status is now considered intermediate risk disease. Here, FLT3 is linked to acute myeloid leukemia.